Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Open-label Study of Afatinib Plus Xentuzumab in EGFR-mutant NSCLC After Prior EGFR TKI
jRCT2080223197Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of xentuzumab in EGFR-mutated non-small cell lung cancer, sponsored by Boehringer Ingelheim. Started May 2016; status: completed.
02
Drugs
xentuzumab
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080223197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223197.